Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.12T
Market cap1.12T
Price-Earnings ratio
40.26
Price-Earnings ratio40.26
Dividend yield
0.56%
Dividend yield0.56%
Average volume
2.30M
Average volume2.30M
High today
$1,192.94
High today$1,192.94
Low today
$1,168.47
Low today$1,168.47
Open price
$1,185.76
Open price$1,185.76
Volume
1.66M
Volume1.66M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$725.31
52 Week low$725.31

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,185.41, giving the company a market capitalization of 1.12T. It carries a P/E multiple of 40.26 and pays a dividend yield of 0.56%.

On 2026-09-30, Eli Lilly(LLY) stock traded between a low of $1,168.47 and a high of $1,192.94. Shares are currently priced at $1,185.41, which is +1.4% above the low and -0.6% below the high.

The Eli Lilly(LLY)'s current trading volume is 1.66M, compared to an average daily volume of 2.3M.

During the past year, Eli Lilly(LLY) stock moved between $725.31 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $725.31 at its lowest and $1,292.65 at its peak.

LLY News

Nasdaq 4h
Lilly's Retatrutide Delivered Significant Weight Loss, A1C Reduction In Phase 3 Trial

(RTTNews) - Eli Lilly and Company (LLY) reported detailed Phase 3 TRIUMPH-2 results showing that Retatrutide delivered substantial weight loss and blood sugar r...

Lilly's Retatrutide Delivered Significant Weight Loss, A1C Reduction In Phase 3 Trial
Nasdaq 7h
Eli Lilly Might Be the Next Stock I Buy

Eli Lilly (NYSE: LLY) continues to gain market share in the weight loss industry. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double...

Eli Lilly Might Be the Next Stock I Buy
Nasdaq 7h
Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip

Key Points Lilly's pipeline is packed with metabolic health programs. Its commercialized metabolic health medicines are big earners. It's also buying assets...

Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Simply Wall St 8h
Eli Lilly Wins FDA Breakthrough Tag For Pancreatic Cancer Drug

Eli Lilly (NYSE: LLY) received FDA Breakthrough Therapy designation for olomorasib in advanced pancreatic cancer, according to a recent company update. The des...

Eli Lilly Wins FDA Breakthrough Tag For Pancreatic Cancer Drug
Nasdaq 10h
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Bristol Myers Squibb maintains a deep portfolio of oncology and immunology treatments while generating high levels of free cash flow. Eli Lilly and...

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 10h
Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

Eli Lilly (LLY) and Company announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, fi...

Nasdaq 10h
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Key Points Viking Therapeutics' recent clinical trial results for its leading weight loss candidate were excellent. But Eli Lilly, the leader in this area, ha...

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Benzinga 15h
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide

Novo Nordisk A/S (NYSE:NVO) announced on Tuesday new real-world evidence demonstrating that escalating semaglutide dosage reduces major adverse cardiovascular e...

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide
TipRanks 16h
Lilly Advances Next-Gen Obesity Combo, Setting Up New Catalyst for LLY

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. This Phase 2 study, officially titled “A Phase 2, Parallel-Group, Double-Blind...

Benzinga 19h
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data

Eli Lilly and Co. (NYSE:LLY) revealed new analysis data indicating that its medications, Zepbound and Foundayo, yielded superior weight loss and blood sugar con...

Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.